CAS 315703-52-7|JK184
Introduction：Basic information about CAS 315703-52-7|JK184, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | JK184 | ||
|---|---|---|---|
| CAS Number | 315703-52-7 | Molecular Weight | 350.437 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C19H18N4OS | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS05, GHS07 | Signal Word | Danger |
Names
| Name | N-(4-ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-amine |
|---|---|
| Synonym | More Synonyms |
JK184 BiologicalActivity
| Description | JK184 is a potent Hedgehog (Hh) pathway inhibitor with IC50 of 30 nM in mammalian cells. |
|---|---|
| Related Catalog | Signaling Pathways >>Stem Cell/Wnt >>HedgehogResearch Areas >>Cancer |
| Target | IC50: 30 nM (Hedgehog)[1] |
| In Vitro | JK184 is designed to antagonize Hh signaling by inhibiting glioma (Gli)-dependent transcriptional activity in a dose dependent manner. JK184 significantly inhibitts proliferation of HUVECs with IC50 of 6.3 μg/mL after three days incubation. To evaluate anti-tumor effect of JK184, MTT assay is conducted in Panc-1 and BxPC-3 cells after administration with indicated concentrations of compounds, half maximal inhibitory concentration (IC50) of JK184 (23.7 ng/mL in anc-1 and 34.3 ng/mL in BxPC-3)[1]. Claudin-low cell lines are more sensitive to JK184 treatment than are MCF10a, MTSV1-7, or HMLE-shGFP and HMLE-pBP cells, and JK184 induced a dose-dependent decrease in glioma-associated oncogene homolog 1 (GLI1) transcript and protein levels in these cells. Treatment with the IC50 dose of JK184 enhances the proportion of HMLE-shEcad cells that stained with Annexin-V, but are negative for propidium iodide (PI) (P<0.0001, t test)[2]. |
| In Vivo | JK184 (5 mg/kg, injected intravenously) exhibits good anti-proliferative activity in subcutaneous Panc-1 and BxPC-3 tumor models, and is a good candidate as antitumor drug targeted Hh signaling. However, JK184 has a poor pharmacokinetic profile and bioavailability[1]. |
| Cell Assay | The Shh-LIGHT2 cells are seeded in 96-well plates and grown to confluency. The Shh-LIGHT2 cells are treated with various concentrations of JK184 micelles or free JK184 or micelles in DMEM containing 0.5% CS, 0.1 mg/mL streptomycin, 100 U/mL penicillin, 5% Shh-N conditioned medium obtained from Shh-N-producing HEK293 cells. The treated cells are cultured further for 60 h, and firefly and Renilla luciferase activities are measured using a dual luciferase kit. Proliferation assay or apoptosis evaluation of HUVECs is measured using MTT method or FCM analysis, respectively. HUVECs are treated with a series concentration of free JK184, JK184 micelles, or blank MPEG-PCL micelles for 48 h, respectively. The mean percentage of cell inhibition or apoptosis is calculated[1]. |
| Animal Admin | Mice[1] Five-week-old female athymic (nu/nu) mice are used. BxPC-3 and Panc-1 tumors are established by s.c. injection of 1×107 cells. Mice bearing tumors around 100 mm3 are selected and randomized into treatment groups (5 mice per group). Mice are injected intravenously every day for 30 days with 100 μL of NS (control), blank micelles, free JK184 (5 mg/kg body weight), or JK184 micelles (5 mg/kg body weight), respectively. Tumor length and width are determined every 3 days and tumor volume (TV) is calculated using the following formula: TV=0.5×length×width2. At the end of experiment, mice are sacrificed. Solid tumors are removed and processed for immunohistochemical analysis and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. |
| References | [1]. Zhang N, et al. Biodegradable polymeric micelles encapsulated JK184 suppress tumor growth through inhibiting Hedgehog signaling pathway. Nanoscale. 2015 Feb 14;7(6):2609-24. [2]. Colavito SA, et al. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Res. 2014 Sep 25;16(5):444. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C19H18N4OS |
| Molecular Weight | 350.437 |
| Exact Mass | 350.120117 |
| PSA | 79.69000 |
| LogP | 4.04 |
| Index of Refraction | 1.683 |
| InChIKey | ROYXIPOUVGDTAO-UHFFFAOYSA-N |
| SMILES | CCOc1ccc(Nc2nc(-c3c(C)nc4ccccn34)cs2)cc1 |
| Storage condition | 2-8℃ |
Safety Information
| Symbol | GHS05, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H318 |
| Precautionary Statements | P280-P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
Synonyms
| HH SIGNALING ANTAGONIST VII |
| N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-amine |
| N-(4-ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-thiazolamine |
| 2-Thiazolamine, N-(4-ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)- |
| N-(4-Ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)thiazol-2-amine |
| JK-184 |
| JK184 |
